Therapeutics

Kymera Therapeutics Unveils IPO Pitch for Protein Degradation

13 days ago   |   By Xconomy

Kymera Therapeutics has a pipeline of preclinical drug candidates that use an experimental approach to get rid of disease-causing proteins and it's now looking to tap the public markets to finance tests of the technology in humans. In paperwork submitted to the Securities and Exchange Commission on Friday, Kymera set a $100 million goal for its IPO. The filing comes three weeks after the Cambridge, MA-based biotech inked a multi-year, multi-product R&D partnership with Sanofi that paid $150 million up front. Kymera is developing drugs that harness protein degradation, a cell's built-in...
Read more ...

 


Search by Tags

   Therapeutics      Protein      BioTech      Biotech      R&D      Drug      Drugs      Boston      Boston blog main      Boston top stories      National blog main      New York blog main      New York top stories      San Francisco blog main      San Francisco top stories      Amgen Ventures      Arvinas Therapeutics      Atlas Venture      Atopic dermatitis      Bain Capital      Bessemer Venture Partners      C4 Therapeutics      Cancer      Cedilla Therapeutics      Clinical trials      Gilead Sciences      Hidradenitis suppurativa      Inflammation      Kymera Therapeutics      Life Sciences      Nello Mainolfi      Nruix Therapeutics      Pfizer      Protein degradation      Roche      Sanofi      Vertex Pharmaceuticals  


World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

2nd International Conference on Tissue Science and Regenerative Medicine

This conference is designed for experts in academia and industries working in the tissue science and regenerative field, this conference will examine cutting-edge research in... Read more ...

How COVID-19 Arose and Amplified Along the Meat Supply Chain

How COVID-19 Arose and Amplified Along the Meat Supply Chain

Early in this unforgettable year, a wet market in Wuhan, China, emerged as a possible step along the way, if not the place of origin, of the outbreak that would seed the... Read more ...

Global Methane Emissions Soaring, But How Much Was Due to Wetlands?

Global Methane Emissions Soaring, But How Much Was Due to Wetlands?

Infographic published with permission from the authors of “Increasing anthropogenic methane emissions arise equally from agricultural and fossil fuel sources.” (Credit: Jackson... Read more ...

Computer System Assurance: A Paradigm Shift Away from Compliance to Quality

Computer System Assurance: A Paradigm Shift Away from Compliance to Quality

Our Professional Services Written by: Gary E. Ritchie, MS, Senior Validation Engineer Consultant, PSC Biotech Corporation The FDA will release the draft guidance on Computer... Read more ...

With FDA Nod, NS Pharma Duchenne Drug Becomes Sarepta Competitor

With FDA Nod, NS Pharma Duchenne Drug Becomes Sarepta Competitor

Duchenne muscular dystrophy patients whose disease is characterized by a particular genetic mutation now have a new treatment option following the FDA's Wednesday approval of a... Read more ...

Perceptive Advisors' LianBio Inks Deals With BridgeBio, MyoKardia

Perceptive Advisors' LianBio Inks Deals With BridgeBio, MyoKardia

Two California biotechs have teamed up with LianBio, a new company launched earlier this week by hedge fund Perceptive Advisors, as part of deals that expand their reach into... Read more ...

F2G Lands $60M for a New Tack on Taking Out Rare Fungal Infections

F2G Lands $60M for a New Tack on Taking Out Rare Fungal Infections

Fungal infections might not immediately come to mind as rare diseases, but growing resistance to older drugs means that patients who develop these infections have limited... Read more ...

Calliditas gets controlling stake, option to buy out Genkyotex and its...

Calliditas gets controlling stake, option to buy out Genkyotex and its failed PBC drug badams Fri, 08/14/2020 - 05:07 Read more ...

17β-Estradiol affects the innate immune response in common carp

Abstract Inflammation is the evolutionary conserved immune response to harmful stimuli such as pathogens or damaged cells. This multistep process acts by removing injurious... Read more ...

Chutes & Ladders-WuXi taps veteran operations head Dong to lead new vaccines...

Chutes & Ladders-WuXi taps veteran operations head Dong to lead new vaccines unit kblankenship Fri, 08/14/2020 - 08:23 Read more ...

Team discovers a new role for a well-known molecule as a plant hormone

Researchers at the University of Maryland have discovered an entirely new role for a well-known plant molecule called ACC, providing the first clear example of ACC acting on... Read more ...